Responses
Regular and young investigator award abstracts
Clinical trials in progress
368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.